Faecal Microbiota Transplantation to Prevent Complications, Progression, and Mortality in Liver Cirrhosis

What this Trial Is About

Researchers are evaluating the effects of faecal microbiota transplantation (FMT) on patients with liver cirrhosis, specifically looking at complications, disease progression, and mortality. This study aims to explore how changing the gut microbiota with FMT impacts gut barrier function, systemic inflammation, and immune function. It is a Phase 2/3 clinical trial involving patients admitted with acute decompensation of liver cirrhosis. Participants will be randomly assigned to one of two groups: one group receives three applications of FMT, and the other group receives a placebo treatment. Following these treatments, all participants will be monitored and followed for one year to observe disease progression and changes in their gut microbiota and immune responses. During the study, patients will undergo regular assessments to track disease status, gut microbiota composition, gut barrier integrity, and immune function. The main outcome measured is the time until death or a new episode of acute decompensation that requires intervention, with follow-up lasting one year. Safety and effectiveness will be closely monitored throughout the study period.

Faecal Microbiota Transplantation for Liver Cirrhosis